Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Brian Elsbernd Sells 62,975 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Catalyst Pharmaceuticals Stock Up 1.3 %

CPRX opened at $21.96 on Friday. The company has a market cap of $2.67 billion, a price-to-earnings ratio of 18.61, a PEG ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.47 and a 52-week high of $24.64. The firm’s fifty day simple moving average is $22.27 and its two-hundred day simple moving average is $21.49.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Robert W. Baird increased their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $32.50.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Park Square Financial Group LLC purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $29,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $3,733,000. Armis Advisers LLC purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $306,000. Mackenzie Financial Corp lifted its holdings in Catalyst Pharmaceuticals by 132.9% during the fourth quarter. Mackenzie Financial Corp now owns 34,531 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 19,705 shares in the last quarter. Finally, Castlekeep Investment Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $1,775,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.